Management therapy: Neuropathic pain associated w/ diabetic peripheral neuropathy Initially, 50 mg tds (150 mg/day), may be increased to 300 mg/day w/in 1 wk.
Patient w/ CrCl of at least 60 mL/min Max: 100 mg tds (300 mg/day).
Postherpetic neuralgia Initially, 75 mg bd, or 50 mg tds (150 mg/day), may be increased to 300 mg/day w/in 1 wk. May be increased further to 300 mg bd or 200 mg tds in patients who do not achieve sufficient pain relief after 2-4 wk, & can tolerate the treatment.
Patient w/ CrCl of at least 60 mL/min 75-150 mg bd, or 50-100 mg tds.
Fibromyalgia Initially 75 mg bd (150 mg/day), may be increased to 150 mg bd (300 mg/day) w/in 1 wk. May be increased further to 225 mg bd (450 mg/day).
Adjunctive therapy of partial onset seizures 75 mg bd or 50 mg tds (total daily dose: ≤150 mg/day). Max: 600 mg/day.
Renal impairment: CrCl 30-60 mL/min Total daily dose: 75 mg/day, 150 mg/day, 225 mg/day, or 300 mg/day, bd or tds;
15-30 mL/min Total daily dose: 25-50 mg/day, 75 mg/day, 100-150 mg/day or 150 mg/day, as a single or in 2 divided doses;
<15 mL/min Total daily dose: 25 mg/day, 25-50 mg/day, 50-75 mg/day or 75 mg/day once daily;
Hemodialysis Adjust daily dose based on renal function & administer supplemental dose, immediately following 4 hrly hemodialysis treatment. Supplemental dose: 25 mg once daily regimen: 25 or 50 mg single dose; 25-50 mg once daily regimen: 50-75 mg single dose; 50-75 mg once daily regimen: 75 or 100 mg single dose; 75 mg once daily regimen: 100 or 150 mg single dose.
Sign Out
